Clinical Trial Update: A Phase 2 Pilot Study of Apixaban for the Prevention of Thromboembolic Events in Patients With Advanced (Metastatic) Cancer [Phase 2]

View source ↗

Summary

Phase 2 pilot study evaluating apixaban to prevent thromboembolic events in patients with advanced cancer; the trial completed and results were posted in 2016.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer
• Pulmonary Embolism
• Venous Thromboembolism

Drugs mentioned

• Eliquis (apixaban)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Thrombosis, Cancer | Phase 2 | Status: COMPLETED | Results posted: 2016-08-16